ArticleJournal, genetic engineering & biotechnology2026
Association of PPARγ (rs1801282) and TCF7L2 (rs7903146) gene polymorphisms and susceptibility of Type 1 diabetes mellitus in Egyptian children.
Article in Journal, genetic engineering & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 1 diabetes mellitus (T1DM) is caused by the autoimmune depletion of β-cells. Non-HLA genes notably peroxisome proliferator-activated receptor gamma (PPARγ) and transcription factor 7-like 2 (TCF7L2)-important regulators of insulin sensitivity and secretion-may affect risk even though HLA loci predominate in heredity. However, their synergistic impact in T1DM are yet unknown, especially in Egyptian children. So, PPARγ (Pro12Ala, rs1801282 C/G) and TCF7L2 (rs7903146 C/T) polymorphisms were examined in relation to T1DM risk in Egyptian children. Ninety-five normal subjects and one hundred T1DM patients were included. The amplification-refractory mutation system-polymerase chain reaction (ARMS-PCR) utilized to genotype these single nucleotide polymorphisms. T1DM patients exhibited higher HbA1c (11.09 ± 2.46% vs. controls 5.04 ± 0.18%; P < 0.001), while there were no the demographic disparities across the groups (P > 0.05 for age, sex, and BMI). There was a strong correlation found between T1DM and the PPARγ rs1801282 variant. The T1DM group had a significantly greater heterozygous CG genotype (10.0%) than controls (1.1%) (OR = 10.44; P = 0.01). Furthermore, patients had a considerably higher minor G allele frequency (12.0% vs. 6.0%; OR = 2.22; P = 0.04), suggesting a greater risk to this condition. Reciprocally, the CC genotype provided protection from T1DM (OR = 0.32; P = 0.03). The TCF7L2 rs7903146 variant, on the other hand, did not show any significant discrepancies in the groups' genotype or allele frequencies. TCF7L2 rs7903146 fails to rise predisposition to T1DM in Egyptian children, however the PPARγ rs1801282 CG genotype and G allele do. Such outcomes point to a possible involvement of PPARγ in the pathophysiology of T1DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.